EYESW (Second Sight Medical Products) Tariff Resilience Score: 5/10 (As of Jul. 02, 2026)


What is Second Sight Medical Products Tariff Resilience Score?

Second Sight Medical Products EYESW Tariff Resilience Score is 5 as of Jul. 02, 2026. The stock has 1 warning sign investors should review.

Second Sight Medical Products has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Second Sight Medical Products has Second Sight's global supply chain and manufacturing dependencies increase tariff vulnerability. The company has limited pricing power but benefits from industry-specific exemptions for medical devices, offering moderate resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Second Sight Medical Products might have Average Resilient.

Second Sight Medical Products  (NAS:EYESW) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Second Sight Medical Products Tariff Resilience Score Related Terms

EYESW vs SONX, LUCD, LHDX: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Second Sight Medical Products's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Second Sight Medical Products Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Second Sight Medical Products's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Second Sight Medical Products (EYESW) has a Tariff Resilience Score of 5 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.
Is Second Sight Medical Products' Tariff Resilience Score too high?
Second Sight Medical Products' current Tariff Resilience Score is 5.
How does Second Sight Medical Products' Tariff Resilience Score compare to SONX and LUCD?
Second Sight Medical Products' Tariff Resilience Score of 5 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Second Sight Medical Products's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Second Sight Medical Products Business Description

Address 13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.